Advertisement

Topics

Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?

18:15 EDT 12 Jul 2017 | Topix

It is difficult to assess which drug, if any, will win out, except that Abemaciclib has a different safety profile from the competition. Eli Lilly is developing Abemaciclib for a number of indications including in Hormone-Receptor-Positive , HER2-negative metastatic breast cancer.

Original Article: Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly's Abemaciclib: Better Than Competition In Breast Cancer?"

Quick Search
Advertisement